Background
==========

Platelets play a central role in haemostasis. Blood vessel injury leads to platelet aggregation and also invokes an inflammatory response leading to the formation of prostanoids like prostaglandin E~2~(PGE~2~) and prostacyclin (PGI~2~). It is known that low concentrations of PGE~2~enhance and high concentrations inhibit platelet aggregation. PGE~2~mediates its effect through four receptors: EP~1~(Gα~q~signalling), EP~3~(three isoforms present; signals via G~i~, G~s~or G~q~based on cell type), EP~2~and EP~4~(G~s~signalling). PGI~2~is known to inhibit platelet aggregation through its IP receptor (G~s~signalling). The role of EP~3~in exacerbating platelet aggregation has been well described. However, the role of EP~4~which acts via the same G protein coupling like IP has not been explored in detail. The aim of this study was to investigate the role of EP~4~in platelet aggregation.

Methods
=======

Platelet aggregation assays were performed *ex vivo*using a platelet aggregation analyser (Aggregometer II). Blood from healthy human donors was used to obtain platelet-rich plasma. Aggregation was induced using ADP or collagen. Different agonists and antagonists were added to investigate their effects on platelet aggregation. Ca^2+^flux changes caused by addition of agonists were also examined using a fluorescent Ca^2+^dye (Fluo-3 AM) by flow cytometry.

Results
=======

As expected, PGE~2~(up to 300 nM) and an EP~3~agonist (sulprostone) enhanced platelet aggregation, whereas an EP~2~-selective agonist (butaprost) seemed to have no effect on platelet aggregation. On the contrary, an EP~4~agonist (ONO AE1-329) inhibited platelet aggregation in a concentration-dependent manner, and this effect could be reversed by using EP~4~antagonists (ONO AE3-208 and GW627368x) but not an IP or a DP antagonist. Inhibition of protein kinase C prevented the inhibitory effect of the EP~4~agonist, while inhibition of adenylate cyclase had no effect. The EP~4~agonist ONO AE1-329 also attenuated Ca^2+^flux in platelets that had been stimulated with ADP.

Conclusion
==========

These results are suggestive of an exclusive EP~4~effect on inhibition of platelet aggregation and EP~4~could be a potential target of antithrombotic therapy.
